Hepatitis C transmission and treatment in contact networks of people who inject drugs by Rolls, David A. et al.
Hepatitis C Transmission and Treatment in Contact
Networks of People Who Inject Drugs
David A. Rolls1*, Rachel Sacks-Davis2,3,4, Rebecca Jenkinson2,4, Emma McBryde5, Philippa Pattison1,
Garry Robins1, Margaret Hellard2,3,4
1Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia, 2Centre for Population Health, Burnet Institute, Melbourne,
Victoria, Australia, 3Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia, 4Centre for Research Excellence in Injecting
Drug Use, Burnet Institute, Melbourne, Victoria, Australia, 5Department of Medicine-RMH, University of Melbourne, Victoria, Australia
Abstract
Hepatitis C virus (HCV) chronically infects over 180 million people worldwide, with over 350,000 estimated deaths attributed
yearly to HCV-related liver diseases. It disproportionally affects people who inject drugs (PWID). Currently there is no
preventative vaccine and interventions feature long treatment durations with severe side-effects. Upcoming treatments will
improve this situation, making possible large-scale treatment interventions. How these strategies should target HCV-
infected PWID remains an important unanswered question. Previous models of HCV have lacked empirically grounded
contact models of PWID. Here we report results on HCV transmission and treatment using simulated contact networks
generated from an empirically grounded network model using recently developed statistical approaches in social network
analysis. Our HCV transmission model is a detailed, stochastic, individual-based model including spontaneously clearing
nodes. On transmission we investigate the role of number of contacts and injecting frequency on time to primary infection
and the role of spontaneously clearing nodes on incidence rates. On treatment we investigate the effect of nine network-
based treatment strategies on chronic prevalence and incidence rates of primary infection and re-infection. Both numbers
of contacts and injecting frequency play key roles in reducing time to primary infection. The change from ‘‘less-’’ to ‘‘more-
frequent’’ injector is roughly similar to having one additional network contact. Nodes that spontaneously clear their HCV
infection have a local effect on infection risk and the total number of such nodes (but not their locations) has a network
wide effect on the incidence of both primary and re-infection with HCV. Re-infection plays a large role in the effectiveness of
treatment interventions. Strategies that choose PWID and treat all their contacts (analogous to ring vaccination) are most
effective in reducing the incidence rates of re-infection and combined infection. A strategy targeting infected PWID with the
most contacts (analogous to targeted vaccination) is the least effective.
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Introduction
Hepatitis C virus (HCV) is a blood-borne virus which
chronically infects over 180 million people worldwide [1], and
disproportionately affects people who injects drugs (PWID). The
sharing of needles, syringes and ancillary equipment is believed to
be the primary means of transmission, accounting for the majority
of new infections [2–4] (,90% in Australia, ,72% in Canada,
and ,54% in the United States). HCV has significant morbidity
and mortality with an estimated 350,000 deaths annually
attributed to HCV-related diseases including cirrhosis and
hepatocellular carcinoma [1]. In the United States more deaths
are now attributed to HCV than HIV [5]. Unlike for hepatitis A or
B, currently there is no preventative vaccine for HCV.
Current treatment for HCV generally ranges from 24–48 weeks
of pegylated interferon and ribavirin depending on the HCV
genotype, IL28B genotype and stage of hepatic fibrosis. Increas-
ingly, HCV treatment is becoming ‘‘response based’’ with the
length of treatment varying based on how quickly a patient’s viral
load becomes undetectable. Current treatments are estimated to
be effective in about 60% [6–8] of cases, again varying depending
on HCV genotype, IL28B genotype and level of hepatic fibrosis.
Treatment rates of infected PWID remain low for a combination
of reasons including lack of awareness by PWID of their infected
status, reluctance by some PWID to undergo treatment due to
significant treatment side effects, reluctance by some clinicians and
health services to treat PWID due to concerns about low levels of
treatment success despite increasing evidence that this is not the
case [9], and concern about high levels of HCV re-infection in
PWID despite limited evidence that this occurs [10–12].
Over the next five years there will be major changes in HCV
treatment. With the advent of direct-acting antiviral medications,
treatment will become more efficacious, of shorter duration and
will have less severe side effects. As well as benefiting individual
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patients, recent mathematical modelling suggests that treating
PWID can lead to a considerable reduction in HCV prevalence
over time due to a decrease in HCV transmission within the
PWID community [13,14].
Previous models of HCV transmission have typically made
some assumption of ‘‘mixing’’ rather than consider the contact
network of PWID (e.g. [15–22], and [2,14,23,24] in the Australian
context) or have lacked an empirically grounded contact network
[25]. Under a homogeneous mixing assumption, members of a
population are assumed to have contact with all other members of
the population [26]. It is increasingly recognised that contact
networks are relevant to the transmission of disease [27,28],
especially close-contact diseases [29]. In the context of HCV and
the ‘‘hidden population’’ of PWID, data collection [30–35] using
network-based methods is largely in its infancy. Network-based
modelling efforts into HCV and PWID contact networks are even
newer. Recently Rolls et al. [36] developed a transmission model
for HCV in conjunction with an empirical snowball sampled
network of PWID and an empirically grounded contact network
model of PWID [37], while Khan et al. [38] have produced a
contact network model of PWID using data from the Social
Factors and HIV Risk study [39,40]. (Limitations of the network
model in [38] are discussed in [37].) To date no modelling of HCV
transmission and treatment with empirically grounded contact
networks has been done.
Most of the research into network-based interventions to limit
disease transmission has involved network contact modification
such as isolation (e.g., for SARS [41]) or vaccination rather than
treatment (e.g., for HCV [21]). Some network-based vaccination
strategies require knowledge about the entire network whereas
others only require information local to individuals. Targeted
vaccination (e.g., [42,43]) involves targeting nodes in decreasing
order of number of contacts, which requires knowing the number
of contacts of all members of the network. Other measures such as
betweenness or closeness centrality, instead of number of contacts,
have also been considered (e.g., [44]). In contrast, ring vaccination
targets all the primary contacts of target cases (as for hepatitis B
[45]), or primary contacts and secondary contacts (i.e., contacts of
primary contacts) as for smallpox eradication [46,47]. Acquaintance
vaccination and its variants [43,48,49] target primary contacts
whose number of contacts are above some predetermined value.
In practice, the entire network is usually unknown, so strategies
requiring local information are most clinically relevant. Research
into these strategies usually assumes the contact network has rare
nodes with very large numbers of contacts (e.g., ‘‘scale-free’’
networks [50]). Such highly connected nodes are sometimes called
‘‘hubs’’. For such a network, compared to vaccinating randomly
chosen nodes, acquaintance vaccination strategies have been
demonstrated to be more effective in reducing outbreak size (e.g.,
[42,43,48,49]). For a contact network without such hubs, the
difference in strategies appears much smaller (e.g. [42,44,51])
although the modelling study by Hartvigsen et al. [52] showed
targeted vaccination against influenza reduced outbreak size
somewhat better than random node selection in simulated
networks without hubs. In the context of HCV treatment, lack
of hubs in the contact network would mean strategies based on
finding and removing hubs as a source of infection will probably
not be particularly advantageous. Moreover, the possibility of re-
infection after treatment means network modelling results that
assume immunity is possible may not apply to HCV.
The study by Porco et al. [47] is notable for considering ring
vaccination including secondary contacts for a smallpox outbreak
on a network without hubs. Instead they use a network model
capturing household structure, in which each individual is a
member of both a fully-connected ‘‘household’’ of mean size four
and a fully-connected non-household workplace/social group of
mean size eight. Probability of transmission is assumed to be
higher in the household group. They find ring vaccination can be
a successful strategy for halting a smallpox epidemic, but do not
compare with other strategies, or use empirically grounded
networks. Furthermore, in contrast to our study, they study
vaccination rather than treatment, after which there is no
possibility of re-infection.
Simulation models provide an effective method to investigate
disease transmission and to conduct controlled experiments to
explore the potential benefits of possible treatment strategies. Here
we explore HCV transmission and possible treatment strategies on
empirically grounded simulated PWID contact networks. Our
work builds on our previous efforts creating both an individual-
based transmission model [36] and an empirically grounded
contact network model of PWID [37] using data collected in
Melbourne, Australia, in a study that used network methods
[34,35]. Using molecular epidemiological techniques, it has
recently been demonstrated that clusters of related HCV infection
in the Melbourne study cohort are correlated with network
distance in the snowball sampled empirical contact network [53],
justifying the use of the empirical contact network as a basis for
studying HCV transmission.
Our network model [37] is from the class of exponential
random graph models (ERGMs) [54–56]. ERGMs are a class of
probabilistic network models grounded in hypotheses about social
processes underlying network formation, and are commonly used
in social network analysis. ERGMs capture network features and
structures relevant to human interaction such as transitive closure,
homophily and social circuit dependence. Transitive closure, sometimes
called clustering, is a key feature of social networks, and refers to the
propensity for triangles to form. It is typified by the adage ‘‘the
friend of my friend is also my friend’’. Homophily is the tendency
to form contacts with others that share similar attributes (e.g., age,
gender). It is typified by the adage ‘‘birds of a feather flock
together’’. Loosely, social circuit dependence captures the idea
that people whose contacts are connected are themselves more
likely to be connected. Recent advances with new ERGM
specifications [57,58] provide sophisticated methodology such that
empirical networks with these features can often be modelled
parsimoniously.
This work studies HCV transmission and treatment in the
context of empirically grounded contact networks. In the context
of treatment we investigate an anticipated HCV treatment rather
than preventative vaccines, starting in a situation where HCV is
essentially endemic, infecting about half the network. We directly
compare a number of network-based interventions in this
population, including ring vaccination with secondary contacts.
In the context of transmission we investigate the role of the
number of contacts and injecting frequency on time to primary
infection and the role of spontaneously clearing nodes on
incidence rates. Importantly, in this study the PWID contact
network model is empirically grounded and the transmission
model includes ‘‘imported infections’’ which recognise both the
limitations around including all network partners in empirical
studies and the limitations of using a static network to model time
intervals longer than those used to define a contact.
Methods
Transmission Model
Details of our transmission model have appeared elsewhere
[36]. In short, it is a stochastic individual-based model which
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simulates HCV transmission within a static network on a week-by-
week basis. Any node in the network can be infected by an infected
network neighbour according to a yes/no probability of sharing
followed by a yes/no probability (p1x) of transmission from a
sharing event. Probabilities of sharing depend on the injecting
frequency of the two nodes (each either less than daily or at least
daily). In addition to infection by network transmission, infections
can also be ‘‘imported’’ meaning the source of infection is not a
network neighbour. Imported infections provide a way to include
risks from under-reporting of network neighbours and small
changes to the network which would otherwise not be included
using a static network model. Most parameter values are based on
values published in the literature. Exceptions to this are the
sharing probabilities and mean incidence rate of imported
infection which are estimated from sharing and infection data
collected in the Melbourne study [34–36], and the probability of
transmission from a sharing event (p1x) which was found by
calibration using infection data and an empirical network from the
Melbourne study [36].
A feature of our model is that a fraction (25% [59] unless
otherwise mentioned) of infected nodes can clear spontaneously in
the acute phase. No acquired immunity is assumed in spontane-
ously clearing nodes so these nodes can and do cycle between
being susceptible and infected. The ability to spontaneously clear
is assigned to nodes randomly prior to simulating transmission,
independent of other features. The set of spontaneously clearing
nodes varies from one simulation to the next. This is further
clarified below in connection with ‘‘burn-in’’. For such nodes, the
duration of each infection is simulated from an exponential
distribution, independent of other durations.
Model calibration for p1x is based on an RNA prevalence of
56% (i.e., 56% of the network is infected.) Thus, simulations
include a burn-in phase in which 30% of the nodes are initially
infected and the simulation proceeds until the prevalence reaches
56% (on average across 200 simulations.) One key difference from
the model described in [36] is that the incidence rate of imported
infection is now allowed to vary according to the prevalence at the
end of the previous week. This recognises that a community-based
treatment strategy would typically also lower the prevalence
beyond the network that we have modelled, and so the rate of
imported infections should be reduced. The mean incidence rate
of imported infection (rimported ) is related to the prevalence (pRNA)
through the equation
rimported~9=56|pRNA ð1Þ
where rimported is measured in person-years (PY) at risk. Notice this
is a linear relationship for which there are no infections if the
prevalence is zero, and the mean rate is 9 per 100 person-years at
risk when the prevalence is 0.56, which agrees with the calibration
in [36]. (The use of a linear relationship can also be supported as a
reasonable approximation, for example, if the numbers of unseen
network partners for a network node have a Poisson distribution.
The result is not shown here for brevity.)
Network Model
Details of our contact network model have been described
elsewhere [37]. In short, the Melbourne study was a network
based data collection from three urban locales in the Melbourne
area from which an empirical contact network was created. Using
molecular epidemiogical techniques [53], correlation between
distances in the empirical contact network and clusters of related
HCV infection have been demonstrated, providing re-assurance
that the empirical contact network is the right network to look at.
For various reasons [36,37], in order to model the transmission
network a contact was defined as two people participating in
injecting behaviour in the same room or place and roughly the
same time, as opposed to a narrower definition requiring a
participant to report actual sharing of a syringe, in the previous
three months. (There was no study question about sharing of
ancillary equipment.) In this sense, the empirical network created
is a network of opportunity for HCV transmission.
Using this empirical network and results from social network
analysis [57,60,61], an ERGM was fit to the data [37]. Table 1
shows the model specification. It is a model for the contact
network in the street drug scene in three suburbs of Melbourne,
Australia. Specifically it models connected components with at
least three people (so no isolates or isolated pairs). The size of the
network was estimated to be about 524 people. The model
includes five parameters for network structure: edge (for control-
ling edge density), isolates (for keeping the number of isolates near
zero), alternating-k-star (which is useful for modelling the node
degree distribution), and alternating-k-triangle and alternating-k-
2-path (useful for modelling both clustering and social circuit
dependence). In addition, four parameters model homophily
effects: location (1, 2, 3), gender (M/F), age (less than 25, greater
than 25), and injecting frequency (less than daily, at least daily). A
positive homophily parameter indicates a propensity for two
PWID to share a network tie when they have that attribute in
common. In this ERGM all four homophily parameters are
positive, although homophily on gender was included for
completeness but not found to be a significant effect [36]. With
this model we can simulate empirically grounded contact networks
with which to simulate HCV transmission.
For the results reported here we use 100 simulated networks,
each of which has 274 nodes. We form these networks by using the
ERGM to simulate many networks with 524 nodes, and keep the
first 100 largest components that have 274 nodes. The size 274
was chosen simply because it was the mode of the distribution of
largest component sizes across 48,000 simulated networks reported
previously [37]. We expect similar results for other big compo-
nents, although using a consistent component size provides the
most controlled comparisons. We focus on the largest component
for the obvious reason that the role of the network is more










Same daily user freq. 0.429
Specification for the PWID contact network ERGM. The first five parameters
model network structure while the last four model homophily effects: location
(1, 2, 3), gender (M/F), age (less than 25, greater than 25), and injecting
frequency (less than daily, at least daily). Positive homophily parameters
indicate a propensity for two PWID to share a network tie when they have that
attribute in common.
doi:10.1371/journal.pone.0078286.t001
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interesting for investigation than in isolated pairs and triples. In
addition, there are modelling challenges around the number of
isolated nodes, pairs and triples in the community because they are
harder to find in a study, and there may even be a separate
network mechanism by which some people actively try to stay in a
small contact network. Such issues are beyond the scope of our
network model, so we focus on the largest component only.
Figure 1 shows a typical network used in this study. Figure 2 shows
the histogram for the number of contacts, or ‘‘node degree’’, of the
same network. In particular, notice these networks do not have
‘‘hubs’’ (i.e., the node degree distribution does not have extreme
outliers characteristic of a ‘‘fat tailed’’ distribution). While we deal
with a single component in isolation, a community model could
easily be imagined as a collection of such components. Since
results reported here are averages across 100 different compo-
nents, combining several such components in a population model
would not change our conclusions.
Model Scenarios
We conducted three sets of simulations. The first set was
designed to investigate the role of network features on the time to
primary infection in the baseline transmission model. (Through-
out, an infection is ‘‘primary’’ if the node was never previously
infected, including in the burn-in phase. Otherwise, an infection is
counted as a ‘‘re-infection’’.) Key parameter values are listed in
Table 2. Other values are the same as previously described [36].
No community treatment strategies were included. To investigate
time to primary infection, 3,000 simulations were performed for
520 weeks beyond the end of burn-in for each of 100 networks.
Each simulation used a different burn-in with its own collection of
randomly assigned seed nodes and spontaneously clearing nodes.
For nodes never infected during the burn-in, the time to primary
Figure 1. Typical simulated PWID network with 274 nodes.
doi:10.1371/journal.pone.0078286.g001
Figure 2. Histogram of node degree for the network shown in
Figure 1.
doi:10.1371/journal.pone.0078286.g002
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infection was recorded if infected during the simulation. If the
node did not become infected, the censored value of 520 was
recorded.
The second set of simulations was designed to investigate the
impact of network features (e.g., arrangement of spontaneously
clearing nodes, number of spontaneously clearing nodes) on the
incidence rate of total infection (i.e., primary or re-infection) in the
baseline transmission model. Again, no community treatment
strategies were included. By creating sets of nested simulations and
fixing certain features (e.g., spontaneously clearing group, number
of spontaneously clearing nodes, etc.) we can isolate their effect on
the incidence rate of total infection. First, groups of spontaneously
clearing nodes were created (referred to as S1, S2, . . ..) Since
spontaneous clearing is assigned randomly, the number and
location of these nodes within the network varies between the
groups. For each group of spontaneously clearing nodes, 15 burn-
ins were simulated each. (So, for the spontaneously clearing group
Si the burn-ins are SiB1, SiB2, . . ., SiB15 and so on.) Across burn-
ins the location of initially infected seed nodes varies. Finally, for
each burn-in, 15 simulations were performed for 52 weeks after
burn-in. (So for burn-in SiBj the simulations are SiBjsim1,
SiBjsim2, . . ., SiBjsim15.) The duration is long enough to perform
investigations while being conservative to the possibility that the
network changes over time.
The third set of simulations was designed to investigate the
effect of treatment strategies on both the incidence rate of infection
and prevalence. For each of the nine treatment strategies, 500
simulations were performed (a different burn-in for each) for each
of seven treatment initiation frequencies (i.e, treatment ‘‘epochs’’
to find and begin treating new people are regularly spaced every 1,
2, 4, 8, 13, 26 or 52 weeks.) This is equivalent to treatment
coverage varying from 3.7–190 treatment initiations per
1000 PWID per year if each epoch corresponds to one treatment
initiation. These simulations cover a period of 156 weeks (i.e.,
three years) following burn-in which provides enough time that
differences between the strategies emerge. We made the following
assumptions about treatments based on projected characteristics of
direct-acting antivirals that are currently under development [62].
Treatment is effective in 80% of people. Only infected people are
treated, and they will not start a new course of treatment if in the
middle of a course of treatment. The duration of treatment is 12
weeks. If treatment is effective the duration of infectiousness was
conservatively estimated to be 10 weeks and if treatment is not
effective they remain infectious throughout treatment. Those who
fail to obtain a sustained virological response (treatment success)
are not eligible to be retreated. Thus, nodes ‘‘available’’ for
treatment are those infected nodes not currently in treatment
without a history of previous treatment failure. For strategies that
treat network contacts as well, all referred contacts begin
treatment in the same week as the person who referred them
(whom we call ‘‘ego’’ in reference to the social network literature).
For these simulations, different burn-ins have different random
collections of spontaneously clearing nodes, different random
collections of nodes for whom treatment is effective, and different
random arrangements of infected nodes at the end of burn-in. By
averaging over the 500 simulations the differences between
strategies can be separated from random ‘‘noise’’. Averaging over
the 100 networks has a similar effect on the random selection of
networks. To further minimise the effects of random noise, the
post-burn-in simulations were also organized as a series of
controlled experiments, where the control group was the baseline
simulations using the results from the 50 000 burn-ins (500 per
network, 100 networks) as initial configurations. Simulations for
each of the nine treatment strategies used the same 50 000 burn-
ins as initial configurations. In total, the investigation of treatment
strategies involved over 3 million post-burn-in simulations (500
simulations69 strategies67 frequencies6100 networks).
We consider nine treatment strategies in all. One strategy uses
no network information, two strategies use ‘‘global’’ information
about the network, and six use information local to individual
nodes. We further describe these strategies here. They are
summarised in Table 3.
1. Treatment strategy: random node selection. The
treatment strategy (‘‘random’’) selects a node at random at each
treatment epoch from the collection of available nodes. Thus, no
network information is used. For this strategy there is a clear, non-
random relationship between the treatment frequency and the
mean number of treatment starts per 1000 PWIDs. For example,
new treatment epochs every fourth week would see 13 people
treated per year or about 47 people yearly per 1000 in a network
component of size 274.
Table 2. Key Model Parameters for Simulations.
Model Parameter Definition Value Reference
Prob. of transmission from one sharing event (p1x) 0.00995 [36]
Rate of importing infection into a node (rimported ) varies [36]
Proportion of spontaneously clearing nodes 0.25 [59,79]
Prevalence at end of burn-in phase 0.56 [36]
Edgewise weekly probability of sharing (both less-frequent users) 0.19 [36]
Edgewise weekly probability of sharing (one less-frequent user) 0.18 [36]
Edgewise weekly probability of sharing (two more-frequent users) 0.24 [36]
Incidence rate ratio for imported infections of freq. vs. non-freq. users 1.3 [36]
Mean time to chronic spontaneous clearance (years) 200 [80]
Duration of latent period (weeks) 2 [81]
Mean time to acute spontaneous clearance (weeks) 7 [79]
Duration of acute phase (weeks) 26 by definition
Key model parameters used for transmission and treatment simulations. Less-frequent users have injecting behaviour less than weekly (on average) while more-
frequent users have injecting behaviour at least weekly (on average). Rate of importing infection [36] is modified to account for varying prevalence.
doi:10.1371/journal.pone.0078286.t002
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2. Treatment strategies: priority by node degree. We
consider two treatment strategies that use ‘‘global’’ information
about the network. That is, at each treatment epoch, the strategies
rank the available nodes in priority order for treatment, either by
order of increasing (‘‘inc. degree’’) or decreasing (‘‘dec. degree’’)
node degree and choose the highest ranked node for treatment.
Taking nodes in decreasing order is analogous to targeted
vaccination. Since knowing all node degrees and knowing the
current infection status of all nodes in the PWID network will both
generally be impossible, these are not practical strategies.
However, they can serve as useful benchmarks. Indeed, amongst
vaccination strategies the best known strategy on scale-free
networks is believed to be targeted vaccination [43]. As with
random node selection, there is a clear, non-random relationship
between the treatment frequency and the mean number of
treatment starts per 1000 PWIDs.
3. Treatment strategies: primary contacts. By analogy
with ring vaccination, for ring treatment (‘‘ring’’), at each
treatment epoch one node (‘‘ego’’) is chosen at random from
those available for treatment, and treated. In addition, all of ego’s
primary contacts (i.e., ego’s ‘‘ring’’) which are available for
treatment, are treated. Across simulations the number of treatment
initiations will vary depending on node degrees and the number of
neighbours actually infected.
We also consider two treatment strategies, analogous to
enhanced acquaintance immununization, in which we treat ego,
chosen at random, and certain members of ego’s ring that are
available for treatment. The criteria for their treatment is that
their number of contacts (i.e., node degree) is at least some cutoff:
either 5 (‘‘acq5’’) or 3 (‘‘acq3’’). Note that unlike enhanced
acquaintance immununization, we also treat ego. Also note that
‘‘acqM’’ (where M is larger than the maximum node degree)
would correspond to random node treatment while acq0 would
correspond to ring treatment (in the absence of isolated nodes.).
4. Treatment strategies: primary and secondary
contacts. We consider two treatment strategies that include
primary and secondary contacts. There are two strategies because
a secondary contact could be defined as all the additional
neighbours of all of ego’s ring (‘‘2-ring all’’), or just the additional
neighbours of the infected members of ego’s ring (‘‘2-ring’’). As with
other strategies, only those available for treatment are treated. As
with the ring strategy, across simulations the number of treatment
starts will vary.
Thus the four strategies ‘‘random’’, ‘‘acq5’’, ‘‘acq3’’, and ‘‘ring’’
capture a spectrum of strategies that begin with a randomly chosen
ego at each treatment epoch and treat an increasing fraction of
ego’s primary contacts, while the ‘‘2-ring’’ and ‘‘2-ring all’’
strategies go even further by treating an increasing fraction of ego’s
secondary contacts too.
5. Treatment strategy: primary contacts of uninfected
nodes. Finally, we consider an additional treatment strategy
(‘‘naive ring’’) which treats the infected primary contacts of
randomly selected HCV-naive (i.e., never infected) nodes. This is
the only strategy for which the randomly chosen node is not
available for treatment. We caution that results for this strategy
must be viewed as preliminary. Our network model does not
explicitly model the contacts of new injectors. Thus, it assumes
their contacts are similar to more experienced injectors, and so
results for this strategy will be the most sensitive to departures from
this assumption. We discuss this further in the Discussion.
Analysis
Network visualisation was created using Pajek [63]. Simulations,
analyses and boxplots were completed using MATLAB [64]. For
incidence rates of infection, infections are counted from the start of
the post-burn-in phase. Incidence rates are computed using the
number of infections and weeks susceptible in the post-burn-in
phase. Nested ANOVA analyses use the anovan function.
Confidence intervals for mean incidence rates and mean
proportions use a Gaussian approximation. Kaplan-Meier esti-
mates were generated using the ecdf function.
Results
Transmission
As expected, both increased numbers of contacts (i.e., node
degree) and increased injecting frequency play key roles in
reducing the time to primary infection. Figure 3 shows median
time to primary infection for node degrees 1–6 and both injecting
frequencies as boxplots across 100 networks. Results for each
network are calculated as the median for each node separately as a
less frequent and a more frequent injector across 3000 HCV
Table 3. Treatment Strategies.
Strategy Short Name Node Selection at each Treatment Epoch
Decreasing node degree dec. degree Choose node avail. for treatment with largest node degree.
Increasing node degree inc. degree Choose node avail. for treatment with smallest node degree.
Random node selection random Choose avail. ego randomly. Treat ego.
Acquaintance, degree $5 acq5 Choose avail. ego randomly. Treat ego & ego’s avail. contacts with node
degree $5.
Acquaintance, degree $3 acq3 Choose avail. ego randomly. Treat ego & ego’s avail. contacts with node
degree $3.
Primary contacts ring Choose avail. ego randomly. Treat ego & ego’s avail. contacts.
Primary & some sec. contacts 2-ring Choose avail. ego randomly. Treat ego, avail. prim. contacts and some
avail. sec. contacts.
Primary and all sec. contacts 2-ring all Choose avail. ego randomly. Treat ego, avail. prim. contacts, and all avail.
sec. contacts.
Contacts of uninfected nodes naive ring Choose uninfected ego randomly. Treat all of ego’s avail. prim. contacts.
Abbreviations: ‘‘avail.’’: available, ‘‘prim.’’: primary, ‘‘sec.’’: secondary.
Treatment strategies considered. In all cases, only infected nodes not currently in treatment and without a history of treatment failure are ‘‘available’’ for treatment.
doi:10.1371/journal.pone.0078286.t003
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simulations. These are then combined by forming the median for
each of the 12 categories for that network. Boxes show the 25-th
and 75-th percentiles. The central line denotes the median, the
whiskers show the range of data not considered outliers, and
outliers are shown individually. Several results are clear. Time to
primary infection is noticeably reduced for each additional sharing
partner when the number of sharing partners is small (e.g. by
about one year between degree 1 and 2). It is also clear that
compared to a node injecting less than daily, the reduced time to
primary infection for nodes injecting at least daily is roughly the
same as the reduced time from having an additional sharing
partner. Finally, the variation in the time to primary infection
across the 100 random networks for fixed node degree and
injecting frequency is small compared to the variation across node
degrees and injecting frequencies. This shows that for our
simulated ERGM networks, once network-wide prevalence and
incidence rate are accounted for (i.e., by burn-in and calibration,
respectively), node heterogeneity plays a larger role than network
variation in determining a node’s time to primary infection.
We investigated the role of spontaneously clearing nodes on the
incidence rate of total infection (i.e., primary or re-infection) using
analysis of variance (ANOVA) and nested models in which the
burn-in group is nested within the particular group of spontane-
ously clearing nodes. The number and locations of spontaneously
clearing nodes varies randomly across the groups of spontaneously
clearing nodes. For a single fixed network of size 274, simulation
results from 15 randomly chosen groups of spontaneously clearing
nodes (S1, S2, . . ., S15) were investigated. The nested ANOVA
results show the effect of the particular group of spontaneously
clearing nodes on the incidence rate of total infection is statistically
significant (Pv0:001). That is, there is a connection between the
spontaneously clearing group and the incidence rate of total
infection, either from their number, location or both. On the other
hand, if 15 groups of spontaneously clearing nodes are chosen such
that all have either 64 or 65 spontaneously clearing nodes (the two
most common values), the spontaneously clearing group is no
longer significant (P~0:47). Since location is the only remaining
feature of the spontaneously clearing nodes that can vary, this
shows that the locations of spontaneously clearing nodes is not
statistically significant for the network-wide incidence rate of total
infection. Given the earlier result, it also means their number (or
proportion since network size is fixed here) is statistically significant.
We repeated the nested ANOVA analysis using simulation
results from nine additional networks of size 274 chosen at
random, to make ten in total. For all ten networks the
spontaneously clearing group was a significant effect in determin-
ing the incidence rate of total infection (i.e., Pv0:001 for all ten).
On the other hand, when the number of spontaneously clearing
nodes in the network was either 64 or 65, the spontaneously
clearing group was not a significant effect on the incidence rate of
total infection at the 5% level in nine of the ten networks (i.e,
Pw0:05 for nine, P~0:035 for one). This is consistent with the
conclusions from the first network.
Treatment
Figure 4 shows the effect of the treatment strategies on incidence
rate of total infection. Results reported here are for weeks 131 to
156 (where week 1 is the first week beyond burn-in and also the
first possible week of treatment.) The vertical axis shows the rate
Figure 3. Median time to primary infection across 100 simulated networks. Boxplots are for results for each of 12 categories (node degrees
1–6; two injecting frequencies) over 100 networks. Injecting behaviour frequency is denoted as ‘‘less’’ (i.e., less than daily) or ‘‘more’’ (i.e., at least
daily). For each network, results are formed from 3000 HCV simulations as the median for each node as both a less frequent and a more frequent
injector, and then the median for each of the 12 groups. Boxes show the 25-th and 75-th percentiles. The central line denotes the median, the
whiskers show the range of data not considered outliers, and outliers are shown individually. More frequent injecting behaviour is approximately
equivalent to being a less frequent injector with one additional network contact.
doi:10.1371/journal.pone.0078286.g003
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per 100 person-years at risk, and is calculated as the means across
500 simulations per network, then the mean (with 95% confidence
intervals) across 100 networks. The horizontal axis shows the
average number of treatment initiations started in weeks 1–156. It
is calculated as the means across 500 simulations per network, then
the mean across 100 networks, and then the mean across 156
weeks. It is reported as the number per year per 1000 PWIDs. For
coordinates in the horizontal direction, 95% confidence intervals
are smaller than +/21 (not shown). The incidence rate of total
infection with 95% confidence interval for the baseline simulations
(‘‘baseline (with 95% CI)’’) is shown for comparison. Mean
treatment starts for ‘‘naive ring’’ are smaller because there are
limited numbers of infected nodes available for treatment around
randomly chosen uninfected nodes. With the exception of ‘‘naive
ring’’ (which starts from never-infected nodes, unlike the other
strategies), for a fixed number of treatment initiations below about
10% per year there is a clear order to the strategies. For all but
‘‘inc. degree’’, as the average number of people commencing
treatment increases, the incidence rate is reduced. In particular,
‘‘dec. degree’’ (often viewed as the best strategy for vaccination) is
shown to be the least effective for treatment. Finally, ‘‘naive ring’’,
starting from never infected nodes, appears most effective at
reducing the total rate of infection.
The use of the network strategies can be seen as a way of
reducing the number of treatments to achieve a desired effect. For
example, the effect from treating 47 randomly chosen infected
people per 1000 PWID (i.e., 13 in a network of 274) is
approximately the same as treating 35 infected people per 1000
using the ring strategy. This difference increases as the treatment
frequency increases.
Figures 5 and 6 show comparable results for incidence rate of
re-infection and primary infection, respectively, for the various
treatment strategies and baseline simulations in weeks 131 to 156.
At least four observations can be drawn. Firstly, incidence rates for
re-infection are noticeably higher than for primary infection,
demonstrating an effect seen in practice in this population [34].
This effect was also observed from simulations in [36] in the
context of spontaneously clearing nodes, where it was explained as
a ‘‘boomerang’’ effect whereby A infects B, A clears spontaneous-
ly, then B re-infects A. The same explanation would apply if A
clears by treatment, since in our simulations neither spontaneous
clearance nor successful treatment convey any acquired immunity.
Secondly, except for ‘‘naive ring’’, an ordering of the strategies
using the incidence rate of re-infection is the same as one using the
incidence rate of total infection. (Recall that ‘‘naive ring’’ is
specifically designed to protect never-infected individuals from
infection by treating their contacts.) To better understand the
effect of treating nodes but not their infected contacts, and to
distinguish the effect of network transmission from the effect of
imported infections, Figure 7 shows the average proportion of
infections that are network-based (i.e., not imported). The vertical
axis shows the proportion of infections in weeks 131 to 156 that
are network-based, calculated as the means over 500 simulations
per network, then the mean (with 95% confidence interval) over
100 networks. Recall that the number of imported infections in
any week depends on the number of susceptibles and the incidence
rate of imported infection through equation (1), while the number
Figure 4. Incidence Rate of Total Infection for Weeks 131–156. Vertical coordinate shows the mean incidence rate of total infection in weeks
131–156, calculated as the mean incidence rates across 500 simulations and then the mean (with 95% confidence interval) across 100 networks.
Horizontal coordinate shows the mean number of treatments started in weeks 1–156, calculated as the means across 500 simulations per network,
then the mean across 100 networks, and then the mean across 3 years. Strategies that choose nodes at random and ignore the infection status of
some (‘‘acq5’’) or all (‘‘dec. degree’’, ‘‘random’’) primary contacts have the largest incidence rate of infection. Conversely, the 2-ring strategies and
‘‘naive ring’’ have the lowest incidence rate of infection. Mean treatment starts for ‘‘naive ring’’ are smaller because there are limited numbers of
infected nodes available for treatment around randomly chosen uninfected nodes.
doi:10.1371/journal.pone.0078286.g004
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of network-based infections depends on the number of susceptibles
and the number of infected nodes in each susceptible node’s
primary contacts. For similar prevalences a higher proportion of
network-based infections is a clear sign that a strategy is less
effective in reducing transmissions from primary contacts.
Unsurprisingly, the strategies that choose nodes at random and
ignore the infection status of some (‘‘acq5’’) or all (‘‘dec. degree’’,
‘‘random’’) primary contacts see the largest increase in the role of
network-based infections. Also notable is the ‘‘inc. degree’’
strategy. At small treatment frequencies, the treated nodes have
few contacts and so are at low risk of re-infection. As treatment
frequency increases the collection of egos getting treatment grows,
and the egos in those collections have increasing numbers of
contacts. With more primary contacts comes increased risk of re-
infection. The results for ‘‘naive ring’’, on the other hand, show a
comparably larger decrease in the proportion of network-based
infections. This is another clear sign that ‘‘naive ring’’ is effectively
reducing infections attributable to network transmission.
Thirdly, with the exception of ‘‘naive ring’’, the differences in
the rate of primary infection between the strategies are negligible.
For ‘‘naive ring’’, a trade-off is at work. By focussing on never
infected nodes, the incidence rate of primary infections can be
lowered, but at the expense of a higher incidence rate of re-
infection for other nodes. Whether there is a net benefit from this
trade-off is a different matter, but Figure 4 suggests there is.
Finally, we note that the additional benefit from ‘‘ring’’ to ‘‘2-
ring’’ is small. In practice, the benefit from using a 2-ring strategy
may be outweighed by the additional complexity of finding and
treating secondary contacts. Cost-benefit analysis comparing these
strategies is left for future work.
Figure 8 shows similar results for the chronic prevalence at week
156 (defined as the proportion of nodes that have been infected
constantly for the last 26 weeks). (Results for prevalence are similar
and not shown for brevity.) Baseline chronic prevalence is 61.0%.
(It rises above the calibration value of 56% in the three years after
burn-in.) Differences between the strategies are small, but the same
ordering is apparent, in which ‘‘dec. degree’’, ‘‘acq5’’ and
‘‘random’’ have the smallest impact and both the ‘‘naive ring’’
and the 2-ring strategies have the largest impact. The relative
prevalence reduction is approximately 3.1% and 5.9% for 10 and
20 treatments per year per 1000 PWID at week 156. Also
apparent is that the differences between strategies are negligible
for treatment frequencies below about 20 per 1000.
Sensitivity Analysis
We conducted a number of additional analyses to assess the
sensitivity of our results to various assumptions. Since we use a
static network model, we assessed the sensitivity of our treatment
results to the choice of the particular weeks after burn-in used for
reporting results. Specifically, we limit the time period of interest
to the first 52 weeks following burn-in. On this shorter period the
assumption of a static network is more realistic. To do this we
calculate the incidence rate of total infection for each of the nine
strategies on weeks 27 to 52 which provides 26 weeks for the
treatments to produce an effect. We calculate the number of
treatments on weeks 1 to 52. Results for the treatment strategies
are qualitatively similar. That is, a ranking of the strategies from
most to least effective is the same. The main difference is that the
size of the impacts were not as great, due to a smaller period for
treatment to have an effect. This is not shown for brevity.
Importantly, this shows that even over a shorter time period in
Figure 5. Incidence Rate of Re-infection for Weeks 131–156. Vertical coordinate shows the mean incidence rate of re-infection infection in
weeks 131–156, calculated as the mean incidence rates across 500 simulations and then the mean (with 95% confidence interval) across 100
networks. Horizontal coordinate shows the mean number of treatments started in weeks 1–156, calculated as the means across 500 simulations per
network, then the mean across 100 networks, and then the mean across 3 years. Strategies that choose nodes at random and ignore the infection
status of some (‘‘acq5’’) or all (‘‘dec. degree’’, ‘‘random’’) primary contacts have the largest incidence rate of infection. Conversely, the 2-ring strategies
have the lowest incidence rate of infection. Mean treatment starts for ‘‘naive ring’’ are smaller because there are limited numbers of infected nodes
available for treatment around randomly chosen uninfected nodes.
doi:10.1371/journal.pone.0078286.g005
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which the assumption of a static network is more realistic, our
conclusions ranking the various treatment strategies do not
change.
We conducted additional simulations to account for uncertainty
in input parameters to our model. In total, 14 additional scenarios
were investigated under five treatment strategies (decreasing
degree, random, ring, 2-ring, naive ring). These are described in
Supporting Information S1. With the exception of a scenario in
which p1x~0 so all infections are from the importing source, our
results consistently show that incidence rates of total infection
under treatment can be ranked in the following order: decreasing
degree.random.ring.2-ring.naive ring.
Finally, to investigate the suitability of our assumption of a static
network, we performed additional analysis on the duration of
edges in our empirical network [36]. As part of the Melbourne
study, respondents reported on the time since first using and last
using with each nominee. Of the 263 edges in our empirical
network, we have such data for 250 edges. In the case of multiple
responses per edge by the same respondent, the first was used. In
the case both respondents reported these durations, those with the
smaller network identifier were used (an arbitrary choice). For this
group, 104 (i.e., 41.6%) report first using with the nominee at least
three years ago. But this ignores right censoring, which occurs if
there is still activity between members of the dyad. We say a dyad’s
duration is right-censored if the last activity was reported to be at
most 75 days ago. Then, 11 durations are not censored (time since
last use: median 91, range 91–1095), 239 are censored, and from
the Kaplan-Meier estimator, 97.0% (95% CI: 94.6% –99.4%) of
these edges have duration at least three years. The 75 day cutoff is
conservative since it is less than the period between interviews.
Larger cutoffs increase the estimated percentage of dyads with
duration at least three years. These estimates do not account for
any possible bias from the network-based sample design.
Discussion
Our results demonstrate the PWID network plays an important
role in hepatitis C transmission through both the number of
contacts and the attributes of one’s sharing partners. Understand-
ing the PWID network is likely to play an important role in the
effective and efficient roll out of HCV treatment of PWID over the
next 20 years. In this study, strategies that include treatment of
both primary and secondary contacts are the most effective in
reducing incidence rates of re-infection and total infection, for
similar numbers of treatment starts.
We have shown that the number of network partners plays an
important, direct role in determining the time to primary
infection. The time to primary infection for someone with six
contacts may be less than half that of someone with one contact.
Our network model also suggests location, age and frequency of
injecting contribute to the configuration of the network, thus
playing an indirect role in risk of infection too. We have also
shown that the difference in time to primary infection between
‘‘less-frequent’’ and ‘‘more-frequent’’ injector is roughly the same
as having one additional network contact. Thus, it may be more
effective for health promotion campaigns to focus on the social
context in which risk behaviours take place (e.g., with whom, with
how many different people), rather than simply focusing on the
behaviours themselves (e.g., sharing injecting equipment).
In the context of treatment, treating an individual without
treating their contacts leaves a reservoir of virus as a source of re-
infection (in the absence of acquired immunity) and so those
Figure 6. Incidence Rate of Primary Infection for Weeks 131–156. Vertical coordinate shows the mean incidence rate of primary infection in
weeks 131–156, calculated as the mean incidence rates across 500 simulations and then the mean (with 95% confidence interval) across 100
networks. Horizontal coordinate shows the mean number of treatments started in weeks 1–156, calculated as the means across 500 simulations per
network, then the mean across 100 networks, and then the mean across 3 years. Differences between strategies are smaller than for the incidence
rate of total infection and re-infection. The ‘‘naive ring’’ strategy, which treats the primary contacts of randomly-chosen never infected nodes (if they
exist) is quite effective. Mean treatment starts for ‘‘naive ring’’ are smaller because there are limited numbers of infected nodes available for treatment
around randomly chosen uninfected nodes.
doi:10.1371/journal.pone.0078286.g006
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treated are at high risk of re-infection. Treatment strategies that
take advantage of the contact network of PWID are more effective
in lowering both the incidence rates of re-infection and total
infection. For similar numbers of treatment starts above about
20 per year per 1000 PWID, the most effective strategies at
lowering incidence rates of re-infection in this study treat infected
primary and secondary contacts of infected PWID as well (i.e., ‘‘2-
ring’’, ‘‘2-ring all’’). The strategy treating primary contacts but not
secondary contacts (‘‘ring’’) was almost as effective. The least
effective strategies treat infected PWID selected at random
(‘‘random’’), or chosen by decreasing numbers of primary contacts
(‘‘dec. degree’’). The lack of effectiveness of ‘‘dec. degree’’ as a
treatment strategy is in stark contrast to the widespread belief that
targeted vaccination is the most effective vaccination strategy. The
possibility of re-infection appears to play an important role in our
results. But our networks lack hubs. An interesting question for
future work is whether the ‘‘dec. degree’’ strategy is relatively more
effective for networks with hubs.
A common way to think of an infectious disease spreading is to
imagine the disease spreading away from an index case at the start
(e.g. SARS, influenza) or end (e.g. smallpox eradication) of an
outbreak. In the context of HCV in Melbourne, Australia, where
half or more of the population of interest (PWIDs) are already
infected, it may more more helpful to think of infection
transmitted into uninfected people. Thus we also studied a strategy
(‘‘naive ring’’) that treats infected primary contacts of uninfected
PWID as a means of protecting their uninfected status. Although
not clinically practical (clinicians will not normally have contact
with uninfected PWID and their close contacts) it serves to
demonstrate what is possible with a network strategy. It was by far
the most effective strategy at reducing the incidence rate of
primary infection and subsequently the incidence rate of total
infection too.
We have demonstrated a reduction in chronic prevalence
through treatment. Martin et al. ([13], Figure 6) reported larger
relative prevalence reductions of about 6.7% and 13% over a
longer five year period for an 80% effective treatment, which are
roughly similar results considering we report over a three year
period. Our results also show a similar ranking to results for
incidence rates, in which decreasing degree shows the smallest
effect, the 2-ring strategies show the largest effect, and the random
strategy is somewhere in between. However, with the exception of
one strategy (‘‘dec. degree’’) the differences between the strategies
are small. This is a consequence of the limited time period under
consideration. Recall that even a difference of two people infected
in a network of size 274 is less than 1% difference in prevalence.
For the differences to appear large requires more time for the
strategies to have an impact. So, here we can show the relative
impact of the strategies on chronic prevalence, but a dynamic
network simulating a longer period is really needed to assess the
size of the differences on the time scale of a long-term public
health intervention.
In the context of HCV transmission we have shown that the
number (and proportion) of spontaneously clearing nodes has a
statistically significant effect on the network-wide incidence rate of
total infection. On the other hand, for a fixed number of such
nodes, their arrangement within the network does not have a
statistically significant effect on incidence rate of total infection.
This suggests that apart from their risk of re-infection, the effect of
Figure 7. Mean proportion of infections that are network-based. Vertical coordinate shows the mean proportion of new infections in weeks
131–156 that are network-based (i.e., not imported), calculated as the mean proportions across 500 simulations and then the mean (with 95%
confidence interval) across 100 networks. Horizontal coordinate shows the mean number of treatments started in weeks 1–156, calculated as the
means across 500 simulations per network, then the mean across 100 networks, and then the mean across 3 years. Strategies that choose high-risk
nodes (i.e., more primary contacts) at random while ignoring the infection status of some (‘‘acq5’’) or all (‘‘dec. degree’’, ‘‘random’’) primary contacts
show a larger fraction of network-based infections. At higher treatment frequencies, ‘‘inc. degree’’ shows an increasing fraction of network-based
infections as higher-risk nodes are treated. The ‘‘naive ring’’ strategy, which treats the primary contacts of randomly-chosen never infected nodes (if
they exist), effectively reduces network-based transmission.
doi:10.1371/journal.pone.0078286.g007
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spontaneously clearing nodes is a local effect [36] in which they
are a lower risk as a source of infection to their primary contacts.
Our work is novel for a number of reasons. 1) Our study
investigates an anticipated HCV treatment, rather than preven-
tative vaccines. 2) Unlike other network-based intervention studies
we do not consider the beginning or the end of an epidemic.
Rather, HCV is essentially endemic, infecting about half the
network. 3) We directly compare a number of network-based
interventions in this population, including ring vaccination with
secondary contacts. 4) The contact network model of PWID is
empirically grounded [37] and demonstrated to capture a number
of features of an empirical contact network. The model uses
recently developed statistical approaches in social network analysis
to include features previously demonstrated to be relevant to
human interaction, such as clustering, attribute-based homophily
and social circuit dependence. Indeed, it is the first PWID network
model to explicitly model social circuit dependence. Moreover,
our network model is not scale-free. 5) The individual-based
transmission model [36] includes nodes that can spontaneously
clear and be re-infected, and transmission of infection from
sources other than network neighbours, at a rate estimated from
empirical data. These ‘‘imported infections’’ recognise both the
limitations of including all network partners in empirical studies
and of using a static network to model time intervals longer than
those used to define a contact.
This study has several limitations. We have modelled a three
year period following burn-in using a static network, which we
recognise is an approximation. As described in Welch et al. [28], a
static network is a natural place to begin research. There is also
strong evidence that the empirical network used as the basis for
our contact network model has a large proportion of injecting
relationships that have persisted over the last three years. This
should not be taken to mean that activity along each dyad occurs
consistently. It was previously estimated that activity along each
edge occurred in about 19% of weeks [36]. How this activity
clusters in time is an interesting issue for a dynamic model.
Nevertheless, the simulations of various treatment strategies show
qualitatively similar results over the first year, so the use of a three
year period is not crucial to our general conclusions on treatment.
Combining HCV transmission with an empirically grounded
dynamic network model is an interesting direction for future work.
Work on this is already under way.
We deliberately considered the use of a treatment rather than a
vaccine because this is a major issue with the considerable
advances in direct-acting antiviral agents, and there is currently no
vaccine for HCV. Necessarily, treatment is targeted at sero-
positive PWID. This differs from the results in Hahn et al. [21]
which considered a prophylactic vaccine. A key difference, of
course, is the latter is also given to HCV-naive individuals which
can provide a greater opportunity to lower primary infection rates.
In addition, those antiviral treatment regimens are expected to
have substantially better tolerability and it should therefore
become possible to treat individuals and their close contacts
simultaneously.
We have not explicitly modelled the arrival of new injectors to
the network. This means our results on the time to primary
infection and ‘‘naive ring’’ treatment strategy assume the contacts
of new injectors are similar to others in the network. Our results on
‘‘naive ring’’ in particular highlight the need for a dynamic
network model as future work, with special emphasis on new
members to the drug-injecting scene. Those people represent a
pool of uninfected people. How they form contacts early in their
injecting careers must play a key role in both their risk of primary
infection and strategies to prevent primary infection. Such a model
would also give an indication of the role of population turnover in
the infecting scene as newer, never-infected people enter the
injecting scene while more experienced, infected people leave.
Figure 8. Chronic prevalence at week 156. Vertical coordinate shows the mean chronic prevalence (defined as the proportion of nodes infected
constantly for the last 26 weeks, calculated as the mean proportions across 500 simulations and then the mean (with 95% confidence interval) across
100 networks. Horizontal coordinate shows the mean number of treatments started in weeks 1–156, calculated as the means across 500 simulations
per network, then the mean across 100 networks, and then the mean across 3 years.
doi:10.1371/journal.pone.0078286.g008
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The treatment strategies considered here do not explicitly target
recent infections or new PWID. As a result differences in the rate
of primary infection between the strategies are negligible (with the
exception of the ‘‘naive ring’’ strategy). We leave study of such
strategies for future work.
We have assumed the probability of infection is constant
throughout the duration of an infection. Currently there is no
consensus on the variability in infectivity following infection, and
we feel any other choice would be arbitrary in the absence of
supporting data. We think the role of increased infectivity in the
first acute phase of infection would be minor over short durations
when over 50% of nodes in the network have already been
infected by the end of burn-in. We also suspect increased
infectivity in the acute phase will be more important for a
dynamic model where the arrival and early days of HCV-
uninfected people in the network are explicitly modelled.
Our transmission model assumes no acquired immunity. Under
this assumption, ‘‘boomerang’’ infections, in which A infects B, A
becomes uninfected, then B infects A, can play an important role
in re-infection. We feel this is a conservative assumption in the
context of a model of the effects of treatment on HCV incidence
and prevalence. Results from empirical studies of HCV re-
infection following spontaneous clearance of prior HCV infection
have been variable, with some reporting much lower rates of re-
infection compared to primary infection [65–69], and others
reporting rates of re-infection equal to or higher than the rates of
primary infection [34,70–73]. Recently, it has been recognised
that much of this variation can be attributed to variation in HCV
testing intervals between studies, where studies with lengthy test
intervals miss spontaneously clearing re-infection that occurs
between HCV tests and therefore underestimate the re-infection
rate [74]. Whilst most empirical studies of HCV re-infection
following successful antiviral treatment have found low rates of re-
infection [10,11,65,67,75,76], studies of HCV re-infection follow-
ing successful antiviral treatment in PWID in prison and HIV-
infected men who have sex with men have found high rates of re-
infection [12,77,78]. With the advent of new highly-effective and
increasingly tolerable treatment regimens, the characteristics of the
people receiving treatment may change and re-infection rates
following successful treatment will need to be closely monitored. If
later clinical results establish that spontaneous clearance or
successful treatment leads to acquired immunity, our model will
overestimate the rate of re-infection and the relative advantages of
the various intervention strategies would change.
The imported infections included in the transmission model
provide a way to model risk of infection from sources other than
primary contacts. It is a modelling device that reflects limitations
in modelling the contact network, which in turn reflects difficulties
with collecting data on this difficult-to-reach population of
individuals. Since this risk of infection is independent of the
contact network and lacks heterogeneity (except for the difference
in incidence rate between less-frequent and more-frequent
injectors), our results should be conservative with respect to
differences between network-based treatment strategies.
Our investigation of contact referral strategies like ring
treatment assumes all infected contacts are treated. In reality,
only a fraction of those contacts would be treated. For example,
some contacts may be unwilling to have their HCV status
determined, while others may reject treatment despite being
infected. Although we have not explicitly modelled these effects, a
number of aspects of our simulation mitigate these differences. We
assume the treatments are only effective in 80% of people, so
incomplete elimination of infection in primary contacts is already
included. Futher, we include importing of infection which means a
node continues to have risk even if all contacts are uninfected.
Finally, the acquaintance immunisation strategies ‘‘acq3’’ and
‘‘acq5’’ treat only a fraction of a node’s primary contacts, thus
giving a sense of the difference incomplete treatment of primary
contacts can make (albeit when untreated primary contacts are not
randomly chosen, but chosen by node degree.).
It would be interesting to do a direct comparison of our network
based HCV model treating random nodes, for example, with a
deterministic mixing model using similar treatments and similar
treatment numbers. This would help aid interpretation of results
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